Objectives: To determine whether a combination of point-of-care (POC) and laboratory glycated haemoglobin A (HbA1c) testing (HbA1c algorithm) is more effective in testing for diabetes in everyday practice in remote Australian Aboriginal primary health care, by providing a more rapid definitive result and diagnosing more cases than the standard glucose algorithm.
Participants: Two hundred and fifty-five Aboriginal Australians aged 15 years or more without confirmed diabetes and due for diabetes testing at participating clinics.
Setting: Six primary health care sites in the Kimberley region of Western Australia from 1 September 2011 to 30 November 2013.
Main outcome measures:
Number of participants with a definitive test result, a completed algorithm and a diagnosis of diabetes; time taken to deliver a test result.
Results: Participants were significantly more likely to have a definitive result within 7 days (249 v 199 of 255 participants; P < 0.001), be followed up if an initial laboratory measurement was abnormal (92 v 74 of 167 participants; P = 0.005), and be diagnosed with diabetes (15 v 4 of 255 participants; P = 0.003) using the HbA1c than with the glucose algorithm. Eight participants subsequently diagnosed with diabetes (four using the HbA1c test, four with additional oral glucose tolerance tests that would not normally have been requested) were incorrectly classified as normal by the glucose algorithm. No participants with normal HbA1c measurements were subsequently diagnosed with diabetes.
Conclusions: Use of POC HbA1c testing and collection of venous blood on the same day for a confirmatory laboratory HbA1c testing if the POC HbA1c value is abnormal may simplify diabetes testing in remote areas, provide more timely diagnoses, and increase case detection.
Using glycated haemoglobin testing to simplify diabetes screening in remote Aboriginal Australian health care settings Capillary blood HbA 1c concentration was measured in a finger-prick blood sample collected by primary health care providers and analysed on a DCA 2000+ Analyzer (Siemens/Bayer). This was the only POC machine available in Kimberley clinics during the period of the study, and is routinely used for assessing diabetic control. The aim of our study was to look at real-world practice, so we did not attempt to change the way staff undertook testing or to maintain or calibrate the machines.
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Venous whole blood samples were collected in fluoride/oxalate tubes (glucose test) or EDTA tubes (HbA 1c test). Normal procedures at each clinic were used to store (whole blood was stored at 4°C) and transport samples to one of the three Kimberley PathWest laboratories. Whole blood samples for HbA 1c testing were transported to the PathWest laboratory in Perth. The distances from the study sites to the Kimberley laboratories ranged from 2 km by road to 650 km by air, and from the Kimberley laboratories to Perth between 1677 km and 2224 km by air. Samples were received in Perth in 1-8 days.
Venous plasma HbA 1c levels were measured as part of routine PathWest work. PathWest uses an automated immunoassay, with anticoagulated whole blood specimens automatically haemolysed by HbA 1c haemolysis reagent in the predilution cuvette on a Cobas Integra 800 analyser (Roche Diagnostics). Total haemoglobin levels were measured colorimetrically, while HbA 1c levels were determined by immunoturbidimetric assay. The ratio of the HbA 1c concentration to that of total haemoglobin in the specimen yielded the final proportionate HbA 1c measurement.
Venous plasma glucose (PG) levels were measured by enzymatic assay (glucose oxidase spectrophotometric dry chemistry) on a Vitros 250 Analyser (Ortho Clinical Diagnostics) at the Kimberley PathWest laboratories.
Comparison of the HbA 1c and glucose algorithms
Participants were classified independently by each model for detecting diabetes. We then determined, using the same participants for each model, whether the HbA 1c algorithm was more likely than the glucose algorithm to:
• provide a rapid definitive result; • detect cases of diabetes.
Initial classification by the HbA 1c algorithm used the POC HbA 1c measurement, or the first laboratory HbA 1c measurement if the POC test was not completed (five cases). Subsequent diagnosis of prediabetes and diabetes was based on POC and/or laboratory HbA 1c measurements as follows.
• Normal: POC or laboratory HbA 1c < 39 mmol/mol (< 5.7%).
• Prediabetes: laboratory HbA 1c = 39-46 mmol/mol (5.7%-6.4%).
• Diabetes: two diagnostic HbA 1c measurements у 48 mmol/mol (у 6.5%).
While ADA and WHO guidelines require two diagnostic laboratory results for diagnosing diabetes in asymptomatic patients, 9,20 we used diagnostic POC results, with laboratory results confirming the diagnosis.
We based the initial classification using the glucose algorithm on the first laboratory PG measurement. Subsequent diagnosis of impaired glucose tolerance and diabetes was based on follow-up glucose tests as follows.
• Normal: PG level < 5.5 mmol/L.
• Indeterminate (equivocal result): fasting PG (FPG) level 5.5-6.9 mmol/L, or random PG (RPG) level 5.5-11.0 mmol/L with no completed follow-up tests.
• Impaired glucose tolerance: OGTT 2-hour PG level 7.8-11.0 mmol/L.
• Diabetes: one diagnostic OGTT result (FPG level у 7.0 mmol/L or 2-hour PG level у 11.1 mmol/L), or two diagnostic glucose measurements (FPG level у 7.0 mmol/L and/or RPG level у 11.1 mmol/L).
It was expected that participants with an initial laboratory HbA 1c value greater than 39 mmol/mol (5.7%) or a glucose level greater than 5.5 mmol/L were to be followed up with further tests (FPG, OGTT, HbA 1c ) to confirm the abnormal result (Appendix). The researchers provided regular reminders to clinics to support follow-up. Participants were diagnosed with diabetes if they met any of the HbA 1c -, OGTT-or glucose-based diagnostic criteria for diabetes, based on all measurements collected during the course of the study.
Barriers to and enablers of screening by each algorithm for detecting diabetes were documented during the study.
Statistical analysis
All analyses were performed with Stata, version 13 (StataCorp). We used the McNemar test for paired nominal data to compare differences between the two algorithms regarding the rates of screening for prediabetes and diabetes; between the rates of their diagnosis; and between the rates of obtaining a definitive result. Point estimates were presented with 95% CIs; the exact P value was used. P < 0.05 was defined as statistically significant. significantly more likely to detect diabetes than glucose testing, and that a definitive result could be obtained more rapidly.
Ethics approval
It is of concern that only four of the 20 participants diagnosed with diabetes were identified with the glucose algorithm. In our study, six participants were diagnosed by OGTT, but four of these had normal FPG values. While our results are based on small numbers, this suggests the FPG is not sufficiently sensitive as a screening test in this population.
In contrast, all participants with a confirmed diagnosis of diabetes were identified by the HbA 1c algorithm as having either diabetes (15 cases) or prediabetes (five cases). Those classified as having prediabetes are expected to be followed up more frequently, reducing the chance of diabetes in these patients being missed for any length of time. HbA 1c testing is clearly more likely to detect diabetes than glucose testing.
Our study had a relatively complicated protocol because it compared two diagnostic algorithms. Unsurprisingly, adherence to these protocols was not always complete, but adherence to OGTT (42%) was better than in another recent Australian study (27%), 22 and better than would be expected from the usual experience of remote Aboriginal health practice. This improvement was probably due to regular reminders provided by the researchers. Initial adherence to HbA 1c testing was excellent, but only 55% of those who required follow-up HbA 1c assessment were actually tested, with staff reporting the following barriers to follow-up testing:
• Waiting for participants to return while fasting, so that blood for HbA 1c and glucose tests could be collected at the same time.
• High workforce turnover. Some clinicians who were reviewing results did not realise that some "patients" were study participants, assuming they had already been diagnosed with diabetes; they considered HbA 1c values of 48-52 mmol/mol (6.5%-6.9%) as indicating good glycaemic control and decided that a further HbA 1c test was unwarranted.
• Field officers tasked with bringing participants to the clinics often had extensive lists of patients; reviewing blood tests was often a lower priority.
2 Glycated haemoglobin (HbA1c) and glucose measurements of 20 participants who received a confirmed diabetes diagnosis* An additional advantage to the patient of an immediate result is that they know straight away whether the result is normal (55% in our study), 17 which would avoid the need to return for a clinical review (charged to MBS). Other potential cost savings include reduced specimen collection (patient and staff time, consumable costs) and transportation of blood samples from remote communities to Perth. Consumer costs, such as patient time, can affect compliance 23 and are thus an important element of diabetes testing in this population. If patients are not having other laboratory blood tests, POC testing will avoid the need for venepuncture, which may make screening more acceptable to some patients, potentially increasing uptake. This can be expected to further improve screening and diagnosis in remote areas and the timeliness of initiating management, including lifestyle advice and pharmacotherapy.
Further research is required to determine the cost-effectiveness of the Kimberley HbA 1c algorithm compared with screening in remote locations by laboratory HbA 1c testing alone, and for using simplified POC accreditation processes.
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Potential barriers to implementing HbA 1c testing include a lack of familiarity with the test as a diagnostic tool. Further, as the MBS rebate has only recently been announced, it is not currently a routine test for people without diabetes. Together with updated protocols, changes to the way laboratories report HbA 1c results of diagnostic tests will be needed to highlight new diagnoses of prediabetes and diabetes.
Modifications of how medical software processes these tests may also be needed, as well as extensive education for health service providers.
A change from glucose to HbA 1c testing would substantially increase the number of people needing active follow-up (93 instances of prediabetes, compared with 7 of impaired glucose tolerance; Box 1), potentially leading to overdiagnosis of prediabetes. While this would add to the workload of health service providers, identifying more people at increased risk could also improve targeting of attempts to reduce risk early in the disease process. Further research is required to consider the appropriateness of the prediabetes cut-point used in our study and whether differing levels of intervention are appropriate within the HbA 1c 39-64 mmol/mol (5.7%-6.4%) range.
The strength of our study is that it reflects the practicalities of diabetes detection in remote locations; staff were trained in-house to use the POC HbA 1c analyser and existing processes for laboratory HbA 1c measurement were used. The limitations of our study included the use of a convenience sample that may not be representative of the entire Kimberley adult Aboriginal population. Further, not all participants with abnormal laboratory measurements could be located for follow-up laboratory tests, resulting in incomplete data, and there were variations in adherence to the study protocol for follow-up tests.
Our study shows that adopting the Kimberley HbA 1c algorithm may simplify the testing process in previously undiagnosed individuals and provide a timelier and more accurate diagnosis of diabetes for Aboriginal people and other high-risk remote populations in Australia and elsewhere in the world.
